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Abstract
Adenosine binds to three G protein-coupled receptors (R) located on the cardiomyocyte (A1-R, A2A-R and A3-R) and provides
cardiac protection during both ischemic and load-induced stress. While the role of adenosine receptor-subtypes has been
well defined in the setting of ischemia-reperfusion, far less is known regarding their roles in protecting the heart during
other forms of cardiac stress. Because of its ability to increase cardiac contractility and heart rate, we hypothesized that
enhanced signaling through A2A-R would protect the heart during the stress of transverse aortic constriction (TAC). Using a
cardiac-specific and inducible promoter, we selectively over-expressed A2A-R in FVB mice. Echocardiograms were obtained
at baseline, 2, 4, 8, 12, 14 weeks and hearts were harvested at 14 weeks, when WT mice developed a significant decrease in
cardiac function, an increase in end systolic and diastolic dimensions, a higher heart weight to body weight ratio (HW/BW),
and marked fibrosis when compared with sham-operated WT. More importantly, these changes were significantly
attenuated by over expression of the A2A-R. Furthermore, WT mice also demonstrated marked increases in the hypertrophic
genes b-myosin heavy chain (b-MHC), and atrial natriuretic factor (ANF) – changes that are mediated by activation of the
transcription factor GATA-4. Levels of the mRNAs encoding b-MHC, ANP, and GATA-4 were significantly lower in
myocardium from A2A-R TG mice after TAC when compared with WT and sham-operated controls. In addition, three
inflammatory factors genes encoding cysteine dioxygenase, complement component 3, and serine peptidase inhibitor,
member 3N, were enhanced in WT TAC mice, but their expression was suppressed in A2A-R TG mice. A2A-R over-expression
is protective against pressure-induced heart failure secondary to TAC. These cardioprotective effects are associated with
attenuation of GATA-4 expression and inflammatory factors. The A2A-R may provide a novel new target for pharmacologic
therapy in patients with cardiovascular disease.
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Introduction
Adenosine is an endogenous purine nucleoside that plays an
important role in protecting the heart during ischemia. The
cardiovascular effects of adenosine (A) are mediated by 4 G-
protein–coupled receptors (A1-R, A2A-R, A2B-R and A3-R), all of
which are expressed in the heart. Activation of A2A -Rs results in
coupling to Gs proteins and activation of adenylyl cyclase [1,2,3]
while activation of the A1- and A3-Rs inhibits adenylyl cyclase and
modulates other signaling pathways regulated by Gi/o. Studies
using murine models in which the A1- and A3-Rs have been
genetically manipulated demonstrate a critical role for these
receptors in cardiac protection during ischemia and reperfusion.
[4,5] By contrast, A2A-Rs have been shown to promote post
ischemic protection through inhibition of inflammatory responses.
[6,7].
Owing at least in part to its pharmacological effects on
neurohormone and cytokine activation, [8,9] adenosine also
affects ventricular remodeling in models of heart failure. For
example, adenosine attenuates detrimental chamber remodeling in
rodents with pressure overload hypertrophy and decreases cell size
in cultured neonatal cardiomyocytes. [10,11,12,13] However, the
role of adenosine receptor-subtypes in cardiac remodeling has not
been fully elucidated. Pharmacologic activation of the A1-R
effectively attenuated the development of cardiac hypertrophy and
prevented heart failure in mice that underwent transverse aortic
constriction (TAC) [11] and mice that were A1-R gene-deficient
had a higher mortality when compared with wild-type controls but
did not demonstrate altered ventricular hypertrophy or increased
cardiac dysfunction. [14] Surprisingly, mice in which the A3-R
had been knocked out demonstrated an improved survival,
decreased fibrosis and hypertrophy and a more robust left
ventricular function after TAC when compared with wild-type
controls. The role of the A2-R in cardiac remodeling has not been
defined.
Previously, we demonstrated that constitutive and cardiac
specific over-expression of the A2A -R induced a hyper-contractile
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phenotype with enhanced calcium handling that prevented heart
failure in a transgenic model [15]. This led us to hypothesize that
signaling through the A2A -R might also have salutary effects on
cardiac remodeling. To test this hypothesis we assessed the effects
of TAC on cardiac morphology, function and gene expression in
wild type mice and in mice with cardiac specific and controlled
(adult) over-expression of the A2a-R.
Sustained myocardial hypertrophy secondary to pressure
overload is a leading cause in the development of heart failure
and sudden death in humans [16,17]. Hemodynamic overload is a
complex physiological stimulus that can lead to marked changes in
myocardial structure and function through various humeral and
mechanical components. The hypertrophic response induced by
pressure overload is associated with marked alterations in cardiac
gene expression, which include reactivation of fetal gene
expression patterns. Many studies demonstrated an increase in
the expression of the fetal gene beta myosin heavy chain (b-MHC)
as a sensitive marker for hypertrophy [18]. Many signaling
pathways have been implicated in cardiac hypertrophy and
subsequent failure. GATA-4 a cardiac restricted zinc finger
transcription factor has been shown to control several genes up
regulated during cardiac hypertrophy including b-MHC, cardiac
troponin-C, atrial natriuretic factor, sodium/calcium exchanger
(NCX), A1-R [19]. With that said, not all hypertrophy is thought
to be deleterious. Animal models of hypertrophy have demon-
strated adaptive hypertrophy with normalized wall stress and full
compensation. For example, Insulin like growth factor (IGF) which
has a signaling system involving Protein kinase B (PKB) has been
described in an adaptive pressure induced process [20]. Athletes
are thought to have physiologic hypertrophy secondary to
endurance training, which is not associated with fibrosis or up
regulation in hypertrophic response genes, and increases in wall
thickness are modest.
Results
We created mice with inducible overexpression of A2A-AR. The
human A2A-AR cDNA was cloned into a cardiac-specific and
inducible controlled vector (TREMHC) composed of a modified
mouse a-myosin heavy chain (a-MHC) minimal promoter fused
with nucleotide binding sites for tetracycline transactivating factor
(tTA) (Fig. 1A). [21] A2A-AR transgenic (TG) mice were
engineered on an FVB background (PolyGene, Zurich, Switzer-
land) and crossed with mice that expressed tTA in the heart
(MHC-tTA; Fig. 1A). In this ‘‘tetracycline-off’’ inducible system,
the stable tetracycline analog doxycycline (DOX) inhibits tTA
transactivation, and it was administered to mice at 300 mg/kg of
mouse diet (Bio-Serv, Frenchtown, NJ). A2A-R transgenic founder
lines expressing low and high levels of A2A-R as shown in
Figure 1B, as evidenced by western blot. The constitutive model
was not placed on doxycycline, while the induced model was
placed on doxycycline during mating and removed after 3 weeks
(Fig. 1C). As seen in Figure 1D, A2A-R was really detectable at 6-
week-old mice by 3 weeks of induction. Mice generation was
confirmed in our previous studies [22,23,24].
At eight weeks of age, A2A-R TG mice demonstrated a
significant increase in fractional shortening by 15–20% compared
with non-transgenic littermates (Fig. 2A, P,0.05, n= 12), but were
otherwise phenotypically normal. In contrast, heart rates and wall
thickness were significantly increased in constitutive expression of
A2A-R mice [23]. The increase in fractional shortening persisted at
24 weeks of age. The systolic intracellular Ca2+ in cardiac
myoyctes from the mice at 10–12 weeks of age was significantly
enhanced as seen in Fig. 2B (p,0.05, 15 cells from 5 mice hearts).
At the same time, the recovery of intracellular Ca2+ were markedly
rapid as shown in Fig. 2C (p,0.05, 23 cells from 5 mice hearts).
As expected, cardiac pressure overload by TAC caused a
significant decrease in cardiac contractile function (Fig. 3A,
Table 1) in WT mice. These changes could be seen as early as
two weeks after TAC and persisted to the end experimental point
at 14 weeks after TAC (p,0.001, n = 17, repeated measures two-
way ANOVA test). The increase in end-systolic and end-diastolic
dimension (Fig. 3B) and a higher heart weight to body weight ratio
(HW/BW) (Fig. 3C) compared with sham-operated controls were
attributed to the contractile dysfunction. More importantly, the
development of left ventricular dysfunction (Fig. 3A & Table 2,
p,0.01, n= 10–17), End systolic dimension (Fig. 3B & Table 2),
heart/body ratio (Fig. 3C, p,0.01,n = 10–17), and cardiac fibrosis
(Fig. 3D, p,0.01, n= 10–17) were markedly attenuated in mice
with inducible, cardiac specific over-expressing A2A-R (Fig. 3A,
3B, 3C, 3D) mice at 14 weeks after TAC.
To assess the effects of pressure overload on gene expression in
A2A-R TG and WT mice with or without pressure overload, we
measured mRNA levels of the hypertrophic response genes ß-
MHC and ANF as well as the transcription factor GATA-4. As
seen in Figure 4, it was indeed that hypertrophic marker genes, the
mRNAs encoding ANP (Fig. 4A, p,0.05, n= 7) and ß-MHC
(Fig. 4B, p,0.05, n = 7), were significantly enhanced by
40.565.8% and 70.763.5%, respectively, in WT mice TAC
group compared to sham group. Of note, these hypertrophic
marker genes were dramatically suppressed in the inducible,
cardiac-specific A2A-R TG mice (Fig. 4A & 4B). In addition, the
mRNA encoding GATA-4, a transcription factor that mediates
the activation of the hypertrophic gene program was expressed at
a significantly lower level in A2A-R TG mice than that in wild type
littermate controls after TAC (Fig. 4C, p,0.01, n= 7–8). Since
overexpression of A1-R is known to cause a decrease in cardiac
function [15], we measured the A1-R mRNA levels in both WT
and A2A-R TG mice. As expected, the WT mice had a significant
increase in A1-R levels 14 weeks (p,0.001 vs sham, n= 6) after
TAC, but not in A2A-R TG mice (p,0.01 vs WT TAC group,
n = 6), as shown in Fig. 4D.
Since it has recently been shown that cardiac inflammation are
one of the major pathological factors involving in the pressure
overload-induced murine heart failure [25,26,27] and activation of
A2A-R are responsible for its anti-inflammatory effects [28,29], we
screened the experimental mice myocardium by gene microarray
and validated the gene changes found in microarray by Q-PCR.
As shown in Figure 5, cysteine dioxygenase 1 (Cdo1), complement
component 3 (C3), and serine (or cysteine) peptidase inhibitor,
member 3N (Serpina3n) were enhanced in WT TAC mice, but
their expression were suppressed in A2A-R TG mice. Interestingly,
toll-like receptor (TLr 7), which synergize with A2A-R agonists and
adenosine to up-regulate VEGF, while simultaneously strongly
down-regulating TNFa expression [30], was increased in A2A-R
TG mice even without TAC (Fig. 5D).
Discussion
The present study demonstrates for the first time that
activation of the A2A-R signaling pathway can modulate the
fibrosis, hypertrophy and subsequent left ventricular dysfunction
that follow TAC using a murine model in which over-
expression of the A2A receptor can be controlled and is cardiac
specific. This model system provides several unique features.
Enhanced expression of the A2A-R: (1) is cardiac specific,
thereby obviating effects of adenosine receptor signaling in the
peripheral vasculature or in the central nervous system; (2) can
Cardioprotection of A2A-Adenosine Receptor
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be ‘‘controlled’’ in order to preclude the known effects of
adenosine receptor signaling on cardiac and neural develop-
ment; and (3) avoids the potentially confounding effects of using
non-selective or partially selective adenosine receptor pharma-
cologic agonists and antagonists.
In concentric hypertrophy induced by pressure overload, it
has been suggested that myocytes grow in width to increase wall
Figure 1. Over-expression of the A2A adenosine receptor in mice myocardium. Mice with constitutive and controlled overexpression of
A2A-R were created. (A & B) Bi-transgenic, cardiac specific doxycyline regulated A2A-R transgenic mice were generated and confirmed there is A2A-R
expression in all of lines; (C & D) A representative diagram of the timeline of gene induction. The constitutive model was not placed on doxycyline
and over expressed A2A-R at birth while the controlled or induced model was placed on doxcycline during mating and removed at the age of 3
weeks.
doi:10.1371/journal.pone.0039919.g001
Figure 2. Effects of cardiac specific A2A-R expression on cardiac funtion and calcium handeling. (A) Echocardiography of mice with
inducible, cardiac restricted expression of A2A-R TG and wild type (WT) mice. Fraction shorting (FS) at 8 week and 24 weeks in A2A-R TG and WT mice
showed persist hyper-contractile phenotype in A2A-R TG mice up to 24 weeks (*p,0.01 vs WT mice, n = 8). (B & C) Calcium transient data showing
increased systolic calcium (B) and rapid calcium re-uptake activity (C) in cardiomyocytes from the A2A-R TG mice at 10 weeks age compared to WT.
Data were expressed as mean6SE. *p,0.01 compared to WT cardiomyocytes, n = 15 cells from 5 mice hearts.
doi:10.1371/journal.pone.0039919.g002
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thickness in order to regulate the pressure induced by increased
wall stress [31,32]. With sustained volume load, the compen-
satory hypertrophy transitions to heart failure and dilation.
Many mechanisms have been implicated in this transition
including, increased collagen and fibrosis, an upset in the
balance between metalloproteinases and their inhibitors, oxida-
tive stress and neurohormal activation [33]. In the present study
the WT mice developed more fibrosis than the A2A-R TG mice
after TAC.
These salutary affects of enhanced A2A-R signaling were
associated with a marked attenuation in the expression of the
hypertrophy-associated genes b-MYC and ANF and the tran-
scription regulatory protein GATA-4. b-MHC is characterized by
low adenosine triphosphate activity and low filament sliding
Figure 3. Effect of TAC on left ventricular hypertrophy and function as measured by Echocardiography. (A) A2A-R mice had preserved
cardiac function and showed tolerance to TAC-induced pressure overload. WT mice developed a significant decrease in cardiac contractile function at
14 weeks after TAC (*P,0.01, repeated measures ANOVA test, n = 17). Of note, contractile function in A2A-R TG mice was slightly decline after TAC.
*p,0.01 vs WT TAC at the same time point. (B &C) WT mice developed into a significant increase in end systolic dimensions (B) and a higher heart
weight to body weight ratio (C).*p,0.01 vs sham group, n = 8–17; #p,0.01 vs WT TAC, n = 10–17. (D) WT mice showed significantly more fibrosis
than A2A-R TG at 14 weeks post TAC. Data was expressed as mean6SE *p,0.01 vs WT, n = 10–17. The basal fibrosis is no difference between WT and
A2A-R TG. Both were below 0.1% of total myocardium area.
doi:10.1371/journal.pone.0039919.g003
Table 1. Effect of TAC on LV hypertrophy and Function as Measured by Echocardiography.
Baseline 2wks 4wks 8wks 14wks
WT A2A -R TG WT A2A -R TG WT A2A -R TG WT A2A -R TG WT A2A -R TG
N 17 10 17 10 17 10 17 10 17 10
HR(b/min) 470611 538611** 499614 517612 481614 506611 454616 495612 50467 45966
FS % 38.361.2 49.862.2** 36.261.2 41.961.2 32.262.0 39.363.2* 29.861.0 39.661.0** 18.460.7 40.960.9**
LVEDD(mm) 3.436.09 3.4060.08 3.4760.09 3.260.09 3.5460.09 3.4360.08 3.6360.06 3.296.09* 3.926.08 3.4860.08**
LVESD(mm) 2.160.08 1.7560.09* 2.2360.01 1.7960.09** 2.46.09 2.260.15 2.566.07 1.9960.07** 3.260.05 2.0260.04**
AWT 0.78160.02 0.95160.07 0.97560.03 0.97660.06 0.83460.13 1.0760.08 0.95660.04 1.1160.07 0.99760.02 1.0660.09
PWT 1.0160.03 1.18760.04 1.19860.06 1.1560.05 1.2260.07 1.2560.05 1.360.08 1.136.06 1.08460.04 1.1760.08
HR: heart rate, beat/minute; FS: fraction shorting; LVEDD: Left Ventricular End Diastolic Diameter; LVESD: Left Ventricular End Systolic Diameter; AWT: anterior wall
thickness; PWT: posterior wall thickness. Values are means 6 SE. *p,0.05, **p,0.01 vs WT at the same time points. The data were assayed by repeated measures two-
way ANOVA followed by Bonferroni multiple comparisons.
doi:10.1371/journal.pone.0039919.t001
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velocity but can generate cross-bridge force with higher economy
of energy consumption [34,35,36]. This suggests that up
regulation of b-MHC can be an early adaptive response to
pressure overload but over time leads to a decrease in contractile
function [37]. Indeed, Dorn et al, suggested that depressed
myocyte contractility after induction of pressure overload hyper-
trophy in aortic banded FVB mice is due in part to transcriptional
up regulation of b-MHC [38]. GATA-4 has been shown to control
several genes up-regulated during cardiac hypertrophy including
b-MHC and ANF [19]. GATA-4 binding sites are thought to be
required for activation of b-MHC and angiotensin II type a
receptor expression - both of which have been implicated in
pathological ventricular hypertrophy [39] and the over expression
of GATA-4 generated cardiac hypertrophy in cultured cardiomy-
ocytes and in mice. [40,41] Thus the finding that the diminished
hypertrophy and failure after TAC in the A2A-R TG mice is
associated with a decrease in GATA-4 expression may imply a link
between A2A-R signaling and the expression of hypertrophy genes.
GATA-4 expression level varies between tissues, between devel-
opmental stages, and in disease states. Although it is often used as a
marker of cardiomyocytes, in fetal heart GATA-4 expression is the
highest in the proepicardium followed by endocardial cushions
and then cardiomyocytes. GATA-4 expression in the adult heart
had been reported to increase by approximately twofold in heart
Table 2. Primers for Q-PCR.
Gene Gene ID Forward Reverse
GATA-4 NM_008092 59-CCA TCT CGC CTC CAG AGT-39 59-CTG GAA GAC ACC CCA ATC TC-39
ANP NM_008725 59 CGT GCC CCG ACC CAC GCC AGC ATG G 39 59 GCC TCC GAG GGC CAG CGA GCA GAG C 39
b-MHC NM_080728 59 - ACT GTC AAC ACT AAG AGG GTC A - 39 59 - TTG GAT GAT TTG ATC TTC CAG GG -39
A1-R NM_001039510 59 AAC ATT GGG CCA CAG ACC TAC TTC 39 59 GAT GGA GCT CTG GGT GAG GAT GA 39
b-actin NM_007393 59 GGA CCT GGC TGG CCG GGA CC 39 59 GCG GTG CAC GAT GGA GGG GC 39
GAPDH NM_008084 59 AAC GAC CCC TTC ATT GAC 39 59 TCC ACG ACA TAC TCA GCA C 39
Cdo1 NM_033037 59-TCT GGT CTC TGA ACT CTA AT-39 59-TAG TCT CCA CAG CAT AGG-39
C3 NM_009778 59-CAT AGC CAA GTT CCT GTA-39 59-ATC TTC TTA TCG CCA TCC-39
Serpina3n NM_009252 59-TGG TGC TGG TGA ATT ATA TC-39 59-GCG TAG AAC TCA GAC TTG-39
Tlr7 NM_133211 59-CTC TAC CTT GTG AAG TTA A-39 59-TAA GAT TGG TGG TGT TAG-39
doi:10.1371/journal.pone.0039919.t002
Figure 4. Effect of TAC on GATA-4, ANP, b-MHC and A1-R expression in A2A-R and WT mice. After 14 weeks of TAC, the total RNA was
isolated from either A2A-R TG or WT mice myocardium. The Q-PCR was performed to check the gene expression of GATA-4 ANP, b-MHC and A1-R.
Data were expressed as mean 6 SE. ’p,0.05 vs sham, #p,0.05 vs WT mice TAC group, n = 6.
doi:10.1371/journal.pone.0039919.g004
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disease [42,43]. However, little is known about the regulatory
sequences that drive cardiac GATA-4 expression. Interestingly,
Gs-protein coupled b-AR promotes GATA-4 signaling associated
with cardiac hypertrophy [44,45,46,47]. By contrast, we reported
here that A2A-R, another Gs protein-coupled receptors that also
signals through activation of adenylate cyclase, appears to
diminshe GATA-4 expression. However, by contrast with the
b1-AR, the A2A-R can also mediate activation of MAPKs and
PKC [48] with subsequent induction of hypoxia-inducible factor 1
[49]. Thus, it might be a PKA-independent pathway that
suppresses GATA-4 expression in myocytes after A2A-R signaling.
However, further studies will be required to test this hypothesis.
Earlier studies have suggested a role for adenosine in
cardioprotection during pressure-induced stress. For example,
treatment with dipyridamole, an adenosine uptake blocker that
increases myocardial adenosine levels, attenuated chamber
remodeling in rats with pressure overload hypertrophy. [10]
Similarly, the adenosine analogue 2-chloroadenosine lowered
both heart to body weight ratios and improved left ventricular
fractional shortening in mice exposed to TAC. [10] Consistent
with these studies, diminished extra-cellular adenosine produc-
tion as a result of a genetic deletion of CD73 exacerbated left
ventricular hypertrophy and dysfunction after pressure overload.
[13] In vitro, all of three adenosine receptors blunt the
phenylephrine-induced rat neonatal cardiomyocytes hypertrophy
[12]. However, the role of the A1- and A3-adenosine receptors
in protecting the heart from the stress of pressure overload
remains less clear. Using the selective A1-adeonsine agonist N
6-
cyclopentyladeonsine (CPA), Liao et al found that A1-R
signaling attenuated TAC-induced changes in left ventricular
fractional shortening and heart to body-weight ratios in C57B6
mice. However, when the A1-R was genetically deleted, TAC
had identical effects on ventricular hypertrophy and dysfunction.
[14] Furthermore, deletion of the A3-R attenuated TAC-
induced left ventricular hypertrophy, fibrosis and dysfunction,
suggesting that over-expression of the A3-R would have a
deleterious effect. Since A1- and A3-R signaling inhibit adenylyl
cyclase, slow heart rate, and inhibit cardiac contractility while
A2A-R signaling increases adenylyl cyclase activity and enhances
cardiac contractility, it is not surprising that these different
adenosine receptor-subtypes have disparate effects in the context
of pressure-induced stress. [15].
A2A-R agonist displays rapid anti-inflammatory properties in a
variety of in vitro and in vivo models [50,51,52]. And cardiac
inflammation is one of the major pathological factors involving in
the pressure overload-induced murine heart failure [25,26,27]. In
the present study, four inflammatory factors are suppressed by
over-expression of A2A-R, which might be attributable to its
salutary effects on cardiac remodeling. Future studies will be
required to determine why the enhanced cardiac specific A2A-R
signaling suppresses myocardial inflammation and what the
molecular relationship is between mycoytes, inflammatory cells,
and fibroblast during enhanced A2A-R signaling.
In summary our study demonstrates that A2A-R over-expression
is protective against pressure-induced heart failure secondary to
TAC. These cardioprotective effects are associated with inhibition
of GATA-4 expression and attenuation of the up-regulation of
hypertrophy gene program that characterizes the pressure
overloaded heart. Taken together, these results suggest that the
A2A-R may be a therapeutic target in the treatment of patients
with hypertension or hypertrophic heart disease.
Figure 5. Effects of TAC on Inflammatory genes expression in A2A and WT Mice. After 14wks of TAC, the total RNA was isolated from A2A-R
TG and WT mice myocardium. The Q-PCR was performed to check the gene expression of cysteine dioxygenase 1 (Cdo1), complement component 3
(C3), serine (or cysteine) peptidase inhibitor, member 3N (Serpina3n), and toll-like receptor (TLr 7). Data was expressed as mean 6 SE. *p,0.05 vs
sham, #p,0.05 vs WT mice TAC group, n = 6. &p,0.05 vs WT sham.
doi:10.1371/journal.pone.0039919.g005
Cardioprotection of A2A-Adenosine Receptor
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Materials and Methods
Transgenic Mouse Generation
Experiments were carried out in transgenic mice with controlled
cardiac restricted over expression of the human A2A-R TG as
previously described [15]. Using a cardiac-specific and inducible
promoter, we selectively over-expressed A2A-R TG in FVB mice
after removal of doxycycline (DOX) from their diet at 3wks.
Animal studies were approved by the Institutional Animal Care
and Use Committee of Thomas Jefferson University.
[Ca2+]i Transient Measurements
Myocytes from A2A-R TG and WT mice were exposed to
0.67 mM of fura-2 AM for 15 minutes at 37uC. Fura-2-loaded
myocytes were field-stimulated to contract (1 Hz, 37uC) in
medium 199 containing 1.8 mM [Ca2+]o. Fura-2-loaded myocytes
mounted on [Ca2+]i transient measurements using a Dvorak-
Stotler chamber situated in a temperature-controlled stage (37uC)
of a Zeiss IM 35 inverted microscope (Thornwood, NY) were
performed as previously described [53].
Surgical Procedure for Transverse Aortic Banding
Eight-week-old male wild-type FVB mice (N=17) and A2A -R
littermates (N= 10) underwent transverse aortic banding (TAC) as
previously described [15]. Briefly, an aortic band was created by
placing a ligature (7-0 nylon suture) securely between the origin of
the right innominate and left common carotid arteries with a 27-
gauge needle as a guide. The sham procedure was identical except
that the aorta was not ligated. Each strain has 8 mice in Sham
group.
In Vivo Assessment of Cardiac Function
Left ventricular (LV) function was evaluated with transthoracic
echocardiography at baseline, 2, 4, 8, 12, and 14Wks. A Visual
Sonic Vevo 770 imaging system was used (Miami, FL). Mice were
lightly sedated with isoflurane. A parasternal short-axis view was
obtained for LV M-mode imaging at the papillary muscle level.
Three independent M-mode images were used for measurements
of LV end-diastolic internal diameter (LVEDD) and LV end-
systolic internal diameter (LVESD) in two consecutive beats
according to the American Society of Echocardiography leading
edge method. Fractional shortening (FS) was calculated as FS%
= [(LVEDD – LVESD)/LVEDD]6100. Anterior (AWT) and
Posterior Wall thickness (PWT) were also measured. Hearts were
harvested at 14 weeks.
Real-Time Polymerase Chain Reaction
Reverse-transcribed cDNA from myocardial mRNA was used
to determine the expression of A2-AR, atrial natriuretic peptide
(ANP), GATA-4, and b-MHC. cDNA was reverse transcribed
from 1mg of total RNA extracted from the left ventricular
myocardium of male mice (n = 6 for each group) with the primers
as shown in table 2. GAPDH and actin genes were used as a
reference for normalization of obtained measurements. Briefly,
40 ng of genomic DNA from mouse tail was used to quantify the
number of transgenes inserted into the genome. Analysis of gene
expression was performed using 2(-delta delta C(T)) method. [54].
Immunoblotting and Histopathology of Myocardium
Picrosirius red staining for assessment of fibrosis was performed
by the Research Animal Diagnostic Laboratory (University of
Missouri). To determine fibrosis, 5 independent high-power fields
of stained images from each animal were analyzed by a blinded
observer with Image-Pro Plus software (MediaCybernetics, Silver
Spring, MD).
Statistics
All results are expressed as means 6 SE. Two-way analysis of
variance was used to analyze the calcium transient. Repeated
measurement ANOVA was used to analyze the contractile
function after TAC. Commercial software package were used for
all statistical analysis (Graph Pad, La Jolla, CA) two group
comparisons were made with the unpaired student t-test. In all
analyses, p,0.05 was taken to be statistically significant.
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